Larvol Delta - VIRTUAL-A-firstinman-phase-III-study-of-OBI3424-an-AKR1C3selective-bisalkylating-agent-prodrug-in-subjects-with-advanced-cancer-including-hepatocellular-carcinoma-HCC-and-castrateresistant-prostate-cancer-CRPC

OBI-3424 - OBI Pharma

https://meetinglibrary.asco.org/record/191750

Apostolia Maria Tsimberidou; Claire F. Verschraegen; Pei Hsu; Tillman E. Pearce

Apr 29, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next